Beskidzkie Centrum Onkologii Szpital Miejski Im. Jana Pawla II W Bielsku-Bialej — Clinical Trial Site

12 Registered trials

3 Currently recruiting

Organisation

Beskidzkie Centrum Onkologii Szpital Miejski Im. Jana Pawla II W Bielsku-Bialej

Location

Bielsko-Biala, Poland

Identifier

ORG-100046855

Address

Wyzwolenia 18, 43-300, Poland

Departments

Katedra i Klinika Onkologii
Oddzial Radioterapii i Chemioterapii
Oddział Onkologiczny
Oddział Onkologiczny i Hematoonkologiczny
Oddział Radioterapii i Chemioterapii
Oncology

Clinical trials at this site (12)

Search interface

Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 patients with incurable, metastatic/recurrent head and 5 2025-01-27
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Gastric cancer, Advanced/Metastatic Gastric cancer, Gas 5 2025-01-17
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Resected High-Risk Stage II Melanoma 5 2018-09-11
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended

2024-515131-30-00 Relapsed / Refractory Metastatic or Advanced Solid Tumo 4 2023-12-18
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 5 2019-06-07
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended

2023-508253-98-00 Gastric or gastroesophageal junction (GEJ) adenocarcino 5 2018-10-05